NZ590115A - Monoclonal antibodies having homosubtype cross -neutralization properties against influenza a viruses subtype h1 - Google Patents

Monoclonal antibodies having homosubtype cross -neutralization properties against influenza a viruses subtype h1

Info

Publication number
NZ590115A
NZ590115A NZ590115A NZ59011509A NZ590115A NZ 590115 A NZ590115 A NZ 590115A NZ 590115 A NZ590115 A NZ 590115A NZ 59011509 A NZ59011509 A NZ 59011509A NZ 590115 A NZ590115 A NZ 590115A
Authority
NZ
New Zealand
Prior art keywords
monoclonal antibodies
properties against
against influenza
viruses
neutralization properties
Prior art date
Application number
NZ590115A
Other languages
English (en)
Inventor
Roberto Burioni
Massimo Clementi
Original Assignee
Pomona Ricerca Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40303127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ590115(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pomona Ricerca Srl filed Critical Pomona Ricerca Srl
Publication of NZ590115A publication Critical patent/NZ590115A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ590115A 2008-05-27 2009-05-27 Monoclonal antibodies having homosubtype cross -neutralization properties against influenza a viruses subtype h1 NZ590115A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000398A ITTO20080398A1 (it) 2008-05-27 2008-05-27 Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
PCT/IB2009/052212 WO2009144667A1 (en) 2008-05-27 2009-05-27 Monoclonal antibodies having homosubtype cross -neutralization properties against influenza a viruses subtype h1

Publications (1)

Publication Number Publication Date
NZ590115A true NZ590115A (en) 2012-08-31

Family

ID=40303127

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ590115A NZ590115A (en) 2008-05-27 2009-05-27 Monoclonal antibodies having homosubtype cross -neutralization properties against influenza a viruses subtype h1

Country Status (17)

Country Link
US (1) US9243054B2 (enExample)
EP (1) EP2294084B2 (enExample)
JP (1) JP5792060B2 (enExample)
KR (1) KR101665146B1 (enExample)
CN (1) CN102124028B (enExample)
AU (1) AU2009252758B2 (enExample)
BR (1) BRPI0912285A2 (enExample)
CA (1) CA2725627C (enExample)
EA (1) EA022855B1 (enExample)
ES (1) ES2555486T5 (enExample)
IL (1) IL209499A (enExample)
IT (1) ITTO20080398A1 (enExample)
MX (1) MX2010012974A (enExample)
NZ (1) NZ590115A (enExample)
SG (1) SG191610A1 (enExample)
WO (1) WO2009144667A1 (enExample)
ZA (1) ZA201009273B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20070066A1 (it) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
ITTO20080964A1 (it) 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv
IT1395961B1 (it) * 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
EP2552485B1 (en) * 2010-03-26 2017-03-08 Pomona Ricerca S.r.l. Full-length immunoglobulins of the igg isotype capable of recognizing a heterosubtype neutralizing epitope on the hemagglutinin stem region and their use as anti-influenza medicament
ITTO20110067A1 (it) * 2011-01-26 2012-07-27 Pomona Ricerca Srl Immunoglobuline intere di isotipo igg atte a riconoscere un epitopo di neutralizzazione eterosubtipica sulla regione stelo (stem region) dell'emoagglutinina e loro uso come medicamento antinfluenzale
CN102241768B (zh) * 2010-05-14 2013-12-25 中国科学院上海生命科学研究院 一种抗甲型h1n1流感病毒血凝素蛋白的抗体
JP2013540701A (ja) * 2010-08-12 2013-11-07 セラクローン サイエンシーズ， インコーポレイテッド 抗赤血球凝集素抗体組成物およびその使用方法
CN101988050B (zh) * 2010-12-09 2012-06-27 湖南出入境检验检疫局检验检疫技术中心 抗h1n1猪流感病毒血凝素蛋白单克隆抗体，杂交瘤细胞株及抗原捕获elisa试剂盒
RU2457243C1 (ru) * 2011-01-11 2012-07-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт вирусологии им. Д.И. Ивановского" Министерства здравоохранения и социального развития Российской Федерации ШТАММ ГИБРИДНЫХ КУЛЬТИВИРУЕМЫХ КЛЕТОК МЫШИ Mus. Musculus - 1E7, ПРОДУЦИРУЮЩИЙ МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, ИММУНОРЕАКТИВНОЕ С БЕЛКОМ ГЕМАГГЛЮТИНИНА ПАНДЕМИЧЕСКОГО ВИРУСА ГРИППА А/IIV-Moscow/01/09(H1N1)sw1
WO2012145572A1 (en) 2011-04-20 2012-10-26 The Trustees Of The University Of Pennsylvania Regimens and compositions for aav-mediated passive immunization of airborne pathogens
WO2013119793A1 (en) * 2012-02-07 2013-08-15 University Of Kansas Chemiluminescent nanoparticles and uses thereof
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
LT3052192T (lt) * 2013-10-02 2020-12-10 Medimmune, Llc Neutralizuojantys antikūnai prieš gripą a ir jų naudojimas
KR101628331B1 (ko) * 2014-03-28 2016-06-08 주식회사 녹십자엠에스 인플루엔자 a 바이러스 특이적 단클론 항체 및 이를 이용한 인플루엔자 감염 치료 및 진단 방법
JP6974943B2 (ja) 2014-05-13 2021-12-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ２種の抗体構築物を発現するａａｖを含む組成物およびこの使用
AU2015289805B2 (en) 2014-07-15 2020-06-25 Humabs Biomed Sa Neutralizing anti-influenza B antibodies and uses thereof
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
US11535665B2 (en) 2015-05-13 2022-12-27 The Trustees Of The University Of Pennsylvania AAV-mediated expression of anti-influenza antibodies and methods of use thereof
PL3303384T3 (pl) 2015-06-01 2022-01-03 Medimmune, Llc Neutralizujące cząsteczki wiążące przeciw grypie i ich zastosowania
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
CA3010313A1 (en) 2016-01-13 2017-07-20 Medimmune, Llc Method of treating influenza a
CA3015347A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
WO2018160573A1 (en) 2017-02-28 2018-09-07 The Trustees Of The University Of Pennsylvania Influenza vaccines based on aav vectors
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
WO2018160582A1 (en) 2017-02-28 2018-09-07 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) clade f vector and uses therefor
KR101972238B1 (ko) * 2017-11-22 2019-04-24 한국생명공학연구원 인플루엔자 a 바이러스 특이적 항체 또는 그의 항원 결합 단편
EP3946613A1 (en) 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza
JP2023551903A (ja) 2020-12-01 2023-12-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組織特異的標的化モチーフを有する新規組成物及びそれを含有する組成物
EP4329885A1 (en) 2021-04-27 2024-03-06 Generation Bio Co. Non-viral dna vectors expressing therapeutic antibodies and uses thereof
JP2025509607A (ja) 2022-03-14 2025-04-11 ジェネレーション バイオ カンパニー 異種プライムブーストワクチン組成物及び使用の方法
CN121175327A (zh) * 2023-05-23 2025-12-19 斯克里普斯研究学院 作为流感疫苗抗原的稳定的血凝素（ha）三聚体
CN121021682A (zh) * 2025-10-29 2025-11-28 山东第一医科大学(山东省医学科学院) 一种抗甲型h1n1亚型猪流感病毒的重组纳米抗体及其制备方法和应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA836080B (en) 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6812024B2 (en) 1987-03-16 2004-11-02 Mcgready Roland Keith Anti-paratopic antibody as an immunogen
US5245015A (en) 1991-04-26 1993-09-14 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
AU1538392A (en) 1991-03-11 1992-10-06 Idec Pharmaceuticals Corporation Methods for selecting antibody reagents; anti-idiotype antibodies; and aids vaccine formulations
DE69333348T2 (de) 1992-03-09 2004-09-16 San Diego Regional Cancer Center, San Diego Anti-idiotypischer Antikörper und seine Verwendung zur Diagnose und Therapie bei HIV-bezogenen Krankheiten
JP3061960B2 (ja) * 1992-09-17 2000-07-10 寳酒造株式会社 抗ヒトインフルエンザウイルス抗体
EP0621339B1 (en) 1992-09-17 2001-10-24 Takara Shuzo Co. Ltd. Immunogenic human influenza A virus haemagglutinin polypeptides
GB9221654D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
JP2996864B2 (ja) 1994-03-30 2000-01-11 寳酒造株式会社 抗体可変領域ｄｎａ
US6057421A (en) 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
CA2339045A1 (en) 1998-07-21 2000-02-03 Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh Anti hepatitis c virus antibody and uses thereof
CA2429946A1 (en) 2000-12-01 2002-07-18 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c
FR2817869B1 (fr) 2000-12-07 2005-01-14 Technopharm Anticorps monoclonal humain dirige contre le virus influenza ou un fragment de celui-ci
US6768004B2 (en) 2001-01-11 2004-07-27 Mueller Sybille Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies
US6964199B2 (en) 2001-11-02 2005-11-15 Cantocor, Inc. Methods and compositions for enhanced protein expression and/or growth of cultured cells using co-transcription of a Bcl2 encoding nucleic acid
WO2003059953A2 (en) 2002-01-17 2003-07-24 Polymun Scientific Immunbiologische Forschung Gmbh Anti-idiotypic antibody inducing hiv-1 neutralizing antibodies
ITRM20020049A1 (it) 2002-01-30 2003-07-30 Biostrands S R L Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
EP2024393A2 (en) 2006-05-15 2009-02-18 Sea Lane Biotechnologies,llc. Neutralizing antibodies to influenza viruses
MY170607A (en) 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
EP2061808A4 (en) 2006-09-15 2009-11-18 Fraunhofer Usa Inc INFLUENZA ANTIBODIES, COMPOSITIONS AND RELATED METHODS
ITTO20070066A1 (it) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv
AU2008300516A1 (en) 2007-09-20 2009-03-26 Bracco Imaging Spa Method for the preparation of new oligoclonal antibodies
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
ITTO20080964A1 (it) 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
EP2552485B1 (en) 2010-03-26 2017-03-08 Pomona Ricerca S.r.l. Full-length immunoglobulins of the igg isotype capable of recognizing a heterosubtype neutralizing epitope on the hemagglutinin stem region and their use as anti-influenza medicament

Also Published As

Publication number Publication date
AU2009252758B2 (en) 2014-07-31
KR101665146B1 (ko) 2016-10-11
MX2010012974A (es) 2011-01-21
IL209499A (en) 2016-10-31
WO2009144667A1 (en) 2009-12-03
CN102124028A (zh) 2011-07-13
ES2555486T5 (es) 2019-02-15
EP2294084A1 (en) 2011-03-16
ES2555486T3 (es) 2016-01-04
EA022855B1 (ru) 2016-03-31
IL209499A0 (en) 2011-01-31
KR20110020865A (ko) 2011-03-03
ITTO20080398A1 (it) 2009-11-28
AU2009252758A1 (en) 2009-12-03
EP2294084B2 (en) 2018-09-05
US20110076265A1 (en) 2011-03-31
EP2294084B1 (en) 2015-09-09
BRPI0912285A2 (pt) 2015-10-20
JP2011524161A (ja) 2011-09-01
CA2725627C (en) 2019-08-06
ZA201009273B (en) 2012-05-01
JP5792060B2 (ja) 2015-10-07
CA2725627A1 (en) 2009-12-03
EA201071365A1 (ru) 2011-08-30
CN102124028B (zh) 2015-05-20
SG191610A1 (en) 2013-07-31
US9243054B2 (en) 2016-01-26

Similar Documents

Publication Publication Date Title
NZ590115A (en) Monoclonal antibodies having homosubtype cross -neutralization properties against influenza a viruses subtype h1
NZ588238A (en) Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes
WO2009053604A3 (fr) Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
AU2013207641A1 (en) Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses
EP1977015A4 (en) MONOCLONAL ANTIBODIES THAT BIND AVIAN AVIAN INFLUENZA VIRUS H5 SUB-CLASS HAEMAGGLUTININ AND USES THEREOF
NZ590890A (en) Neutralizing anti-influenza a virus antibodies and uses thereof
WO2009035420A8 (en) Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus h5-subtype or n1-subtype and uses thereof
MX2021007679A (es) Anticuerpos humanos para hemaglutinina de influenza.
WO2008110937A3 (en) Antibodies against h5n1 strains of influenza a virus
NZ604643A (en) S100a4 antibodies and therapeutic uses thereof
IL226957B (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
MX352338B (es) Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
SG172333A1 (en) Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof
NZ606087A (en) Influenza vaccine
WO2008054481A3 (en) Improved inactivated influenza virus compositions
WO2012112489A3 (en) Compositions and methods for the therapy and diagnosis of influenza
GB2467491A8 (en) Humanized anti-Venezuelan equine encephalitis virus recombinant antibodies.
BRPI0811499A2 (pt) Métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral.
PH12020551051A1 (en) Human antibodies to influenza hemagglutinin
PH12014500369A1 (en) Influenza h5 vaccines
WO2010040572A3 (en) Antibodies against h5n1 influenza viruses
WO2009054708A3 (en) Antibody therapy for highly pathogenic avian influenza virus
WO2010028072A3 (en) Avian antibodies specific to influenza virus and technologically simple methods of their manufacture and use
EP3904380A4 (en) MONOCLONAL ANTIBODIES SPECIFIC TO THE PB2 ANTIGEN OF HUMAN INFLUENCE VIRUS (FLU), NUCLEOTIDE SEQUENCES, METHODS AND DIAGNOSTIC KIT FOR INFLUENCE INFECTION
WO2011138032A3 (en) Universal influenza vaccines and methods for their generation

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 MAY 2016 BY DENNEMEYER SA

Effective date: 20130409

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2017 BY DENNEMEYER + CO

Effective date: 20160422

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2018 BY DENNEMEYER + CO

Effective date: 20170427

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2019 BY DENNEMEYER + CO

Effective date: 20180423

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2020 BY DENNEMEYER + CO.

Effective date: 20190419

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2021 BY PETRA OLK

Effective date: 20200519

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2022 BY DENNEMEYER + CO.

Effective date: 20210517

LAPS Patent lapsed